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Masaaki MIZUN02 and J un Y OSHIDA 2 
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The anticancer activity of cationic multilamellar liposomes containing human IFN-βgene (IAB-I) 
against renal cel carcinoma (RCC) was examined. Concentrations of IFN-s protein were measured 
by an enzyme-linked immunosorbent assay. The cytotoxic activity of IAB-I against RCC cells and 
normal renal proximal tubule endothelial cells (RPTEC5899) was examined by the microculture 
tetrazolium dye assay. For the in vivo study， the NC65 RCC cel line was inoculated into severe 
combined immunodeficiency mouse. The RCC cells treated with IAB-I secreted significant amounts 
ofIFN-s protein. Significant in vitro cytotoxic activity ofIAB-I against RCC cells was observed. In 
contrast， treatment of RCC cells with recombinant IFN-s protein resulted in less cytotoxicity. No 
significant cytotoxicity was seen in RPTEC5899 cels. Apoptosis was observed in RCC cells treated 
with IAB-l. The size of NC65 RCC cancers transfected with IAB帽 1in mice was significantly smaller 
than that receiving injection of empty liposomes or recombinant IFN-s protein. These findings show 
that IAB-I may have significant antitumor activity against RCC， and suggest its potential clinical 
application for gene therapy against RCC. 
(Hinyokika Kiyo 51: 71-73， 2005) 
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2， 5-diphenyltetrazolium bromide assayにて検討し
た.アポトーシスは terminaldeoxynucleotidyl 
transferase-mediated UTP nick end labeling 
(TUNEL) methodにて検出した. また， interferon-
stimulated response element (ISRE)の活性を mer-
cury pathway profiling systemを用いて，種々の遺
伝子発現を macroarray. western blottingにて測定




Trans-well system assayでは， IAB-Iの細胞障害











量依存性に認められた. IAB-I (30μJ)を週3回， 2 
週間投与と，週2回， 3週間投与との抗腫蕩効果の差




In vivoモデルとして， severe combined immuno-







この IAB・1による細胞障害活性は， IFN-β 蛋白より
も有意に強く認められた. また，この活性は，濃度依





NC65腎癌細胞の IAB-I処理により I型 IFNsig-
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Fig. 1. Cell viability of IAB-I transfected NC65 cels. 
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Fig. 2. In vivo effect of treatment schedule on IAB・lantitumor activity. 
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